非瓣膜性心房颤动患者新型口服抗凝药物研究进展

被引：3

作者：

宋鑫宇

唐惠芳

机构：

[1] 南华大学附属第一医院

来源：

现代医药卫生 | 2015年 / 31卷 / 08期

关键词：

心脏瓣膜; 心房颤动; 抗凝药; 投药,口服; 抗凝血酶类; Xa因子抑制剂; 综述;

D O I：

暂无

中图分类号：

R541.75 [];

学科分类号：

1002 ; 100201 ;

摘要：

<正>心房颤动(简称房颤)是临床常见的持续性心律失常之一。房颤最严重的后果是栓子脱落导致脑卒中,因此对于房颤患者治疗关键在于预防脑卒中的发生[1]。经现有的风险评估,房颤患者长期应用口服抗凝药物可降低卒中或系统性栓塞的风险[2]。因华法林研究证据较充分,目前临床应用较为普遍,但因其存在一些不足,例如剂量个体差异大及频繁监测凝血指标等,限制了华法林的应用[3-4]。新型口服抗凝药物弥补了华法林的

引用

页码：1167 / 1170

页数：4

共 12 条

[1] 达比加群酯用于非瓣膜病心房颤动患者卒中预防的临床应用建议 [J].

中华心血管病杂志编辑委员会血栓栓塞防治循证工作组 .

中华心血管病杂志, 2014, (03) :188-192

[2] Retrospective investigation of hospitalized patients with atrial fibrillation in Mainland China [J].

Qi, WH .

CHINESE MEDICAL JOURNAL, 2004, 117 (12) :1763-1767

[3]

Use of Apixaban and Warfarin in Patients Undergoing Invasive Procedures: Insights From Aristotle [J] . R.D. Lopes,D.A. Garcia,D. Wojdyla,P. Dorian,J.H. Alexander,L. Wallentin,F. Lanas,M. Hanna,C. Held,C.B. Granger.&nbsp&nbspCanadian Journal of Cardiology . 2013 (10)

[4] Association of atrial fibrillation with mortality and disability after ischemic stroke [J].

McGrath, Emer R. ;

Kapral, Moira K. ;

Fang, Jiming ;

Eikelboom, John W. ;

O'Conghaile, Aengus ;

Canavan, Michelle ;

O'Donnell, Martin J. .

NEUROLOGY, 2013, 81 (09) :825-832

[5] The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study [J].

Connolly, Stuart J. ;

Wallentin, Lars ;

Ezekowitz, Michael D. ;

Eikelboom, John ;

Oldgren, Jonas ;

Reilly, Paul A. ;

Brueckmann, Martina ;

Pogue, Janice ;

Alings, Marco ;

Amerena, John V. ;

Avezum, Alvaro ;

Baumgartner, Iris ;

Budaj, Andrzej J. ;

Chen, Jyh-Hong ;

Dans, Antonio L. ;

Darius, Harald ;

Di Pasquale, Giuseppe ;

Ferreira, Jorge ;

Flaker, Greg C. ;

Flather, Marcus D. ;

Franzosi, Maria Grazia ;

Golitsyn, Sergey P. ;

Halon, David A. ;

Heidbuchel, Hein ;

Hohnloser, Stefan H. ;

Huber, Kurt ;

Jansky, Petr ;

Kamensky, Gabriel ;

Keltai, Matyas ;

Kim, Sung Soon ;

Lau, Chu-Pak ;

Le Heuzey, Jean-Yves ;

Lewis, Basil S. ;

Liu, Lisheng ;

Nanas, John ;

Omar, Razali ;

Pais, Prem ;

Pedersen, Knud E. ;

Piegas, Leopoldo S. ;

Raev, Dimitar ;

Smith, Pal J. ;

Talajic, Mario ;

Tan, Ru San ;

Tanomsup, Supachai ;

Toivonen, Lauri ;

Vinereanu, Dragos ;

Xavier, Denis ;

Zhu, Jun ;

Wang, Susan Q. ;

Duffy, Christine O. .

CIRCULATION, 2013, 128 (03) :237-243

[6]

Efficacy and safety of dabigatran etexilate and warfarin in ‘real world’ patients with atrial fibrillation: A prospective nationwide cohort study [J] . Torben Bjerregaard Larsen,Lars Hvilsted Rasmussen,Flemming Skj?th,Karen Margrete Due,Torbj?rn Callréus,Mary Rosenzweig,Gregory Y.H. Lip.&nbsp&nbspJournal of the American College of Cardiology . 2013

[7]

Risk of Stroke or Systemic Embolism in Atrial Fibrillation Patients Treated With Warfarin: A Systematic Review and Meta-analysis [J] . Ida Ehlers Albertsen,Lars Hvilsted Rasmussen,Thure Filskov Overvad,Tina Graungaard,Torben Bjerregaard Larsen,Gregory Y.H. Lip.&nbsp&nbspStroke . 2013 (5)

[8]

Discovery of Anticoagulant Drugs: A Historical Perspective [J] . Antonio Gomez-Outes,M Luisa Suarez-Gea,Gonzalo Calvo-Rojas,Ramon Lecumberri,Eduardo Rocha,Carmen Pozo-Hernandez,Ana Isabel Terleira-Fernandez,Emilio Vargas-Castrillon.&nbsp&nbspCurrent Drug Discovery Technologies . 2012 (2)

[9] Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range [J].

Connolly, Stuart J. ;

Pogue, Janice ;

Eikelboom, John ;

Flaker, Gregory ;

Commerford, Patrick ;

Franzosi, Maria Grazia ;

Healey, Jeffrey S. ;

Yusuf, Salim .

CIRCULATION, 2008, 118 (20) :2029-2037

[10]

Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control [J] . Christopher Ll. Morgan,Phil McEwan,Andrzej Tukiendorf,Paul A. Robinson,Andreas Clemens,Jonathan M. Plumb.&nbsp&nbspThrombosis Research . 2008 (1)

← 1 2 →